Suche senden
Hochladen
H pylori poster-web
•
2 gefällt mir
•
1,397 views
Elsa von Licy
Folgen
Melden
Teilen
Melden
Teilen
1 von 1
Jetzt herunterladen
Downloaden Sie, um offline zu lesen
Empfohlen
Europeana e cultura italia per lo sviluppo del semantic web e dei linked open...
Europeana e cultura italia per lo sviluppo del semantic web e dei linked open...
libriedocumenti
Evaluation Ultrasonique Des StéNoses Carotidiennes
Evaluation Ultrasonique Des StéNoses Carotidiennes
ARMVOP Médecin Vasculaire
Pr+El+Khattabi+PID+U+2022.pdf
Pr+El+Khattabi+PID+U+2022.pdf
OmarBlach
Gene Xpert & Advances
Gene Xpert & Advances
AIIMS, New Delhi, India
Xpert MTB RIF
Xpert MTB RIF
Dr. Rajat Prakash
Traitements endoscopiques du cancer bronchique
Traitements endoscopiques du cancer bronchique
Patou Conrath
Xpert MTB/RIF Ultranewer technologypast to future DIAGNOSIS OF TUBERCULOSIS
Xpert MTB/RIF Ultranewer technologypast to future DIAGNOSIS OF TUBERCULOSIS
Society for Microbiology and Infection care
Phenotypic methods used in antimicrobial susceptibility testing
Phenotypic methods used in antimicrobial susceptibility testing
ILRI
Empfohlen
Europeana e cultura italia per lo sviluppo del semantic web e dei linked open...
Europeana e cultura italia per lo sviluppo del semantic web e dei linked open...
libriedocumenti
Evaluation Ultrasonique Des StéNoses Carotidiennes
Evaluation Ultrasonique Des StéNoses Carotidiennes
ARMVOP Médecin Vasculaire
Pr+El+Khattabi+PID+U+2022.pdf
Pr+El+Khattabi+PID+U+2022.pdf
OmarBlach
Gene Xpert & Advances
Gene Xpert & Advances
AIIMS, New Delhi, India
Xpert MTB RIF
Xpert MTB RIF
Dr. Rajat Prakash
Traitements endoscopiques du cancer bronchique
Traitements endoscopiques du cancer bronchique
Patou Conrath
Xpert MTB/RIF Ultranewer technologypast to future DIAGNOSIS OF TUBERCULOSIS
Xpert MTB/RIF Ultranewer technologypast to future DIAGNOSIS OF TUBERCULOSIS
Society for Microbiology and Infection care
Phenotypic methods used in antimicrobial susceptibility testing
Phenotypic methods used in antimicrobial susceptibility testing
ILRI
Semio respiratoire
Semio respiratoire
dastane
Rickettsia and chlamydia
Rickettsia and chlamydia
Samer Bio
Cochlée et voies cochléaires
Cochlée et voies cochléaires
Abdelhak Messalti
Ag hbs positif que faire
Ag hbs positif que faire
Salim KHELIF
Line probe assay 26 7-15
Line probe assay 26 7-15
Yahya Noori, Ph.D
Charlotte pbh du16
Charlotte pbh du16
odeckmyn
Bronchite aiguë
Bronchite aiguë
Dr. Kerfah Soumia
Le système circulatoire ah
Le système circulatoire ah
Eya Nasraoui
Cours de sémiologie
Cours de sémiologie
killua zoldyck
Tuberculose extra-pulmonaire
Tuberculose extra-pulmonaire
Dr. Kerfah Soumia
H. pylori past, present and future
H. pylori past, present and future
Sameh Badr
Ulcer
Ulcer
Shimranz Skillls
Git 4th 5th Gastritis.
Git 4th 5th Gastritis.
Shaikhani.
Usman h.pylori
Usman h.pylori
Muhammad Ameen Rashid Qazi
Peptic ulcer disease
Peptic ulcer disease
Pratik Rahate
annurev-med-042220-020814.pdf
annurev-med-042220-020814.pdf
ArlenElisa1
Helicobacter pylori associated Peptic ulcer disease
Helicobacter pylori associated Peptic ulcer disease
S M Ali Hasan
Diagnosis and Treatment of Helicobacter Pylori Infection
Diagnosis and Treatment of Helicobacter Pylori Infection
DLambertus
H Pylori Management 2023 .pptx
H Pylori Management 2023 .pptx
DrChernHaoChong
Regional Antibiotic Resistance Of Helicobacter Pylori
Regional Antibiotic Resistance Of Helicobacter Pylori
Melissa Dudas
Aetiopathophysiology of peptic ulcer diesese
Aetiopathophysiology of peptic ulcer diesese
Prince Lathiya
H.Pylori
H.Pylori
sunilthomasgeorge217
Weitere ähnliche Inhalte
Was ist angesagt?
Semio respiratoire
Semio respiratoire
dastane
Rickettsia and chlamydia
Rickettsia and chlamydia
Samer Bio
Cochlée et voies cochléaires
Cochlée et voies cochléaires
Abdelhak Messalti
Ag hbs positif que faire
Ag hbs positif que faire
Salim KHELIF
Line probe assay 26 7-15
Line probe assay 26 7-15
Yahya Noori, Ph.D
Charlotte pbh du16
Charlotte pbh du16
odeckmyn
Bronchite aiguë
Bronchite aiguë
Dr. Kerfah Soumia
Le système circulatoire ah
Le système circulatoire ah
Eya Nasraoui
Cours de sémiologie
Cours de sémiologie
killua zoldyck
Tuberculose extra-pulmonaire
Tuberculose extra-pulmonaire
Dr. Kerfah Soumia
Was ist angesagt?
(10)
Semio respiratoire
Semio respiratoire
Rickettsia and chlamydia
Rickettsia and chlamydia
Cochlée et voies cochléaires
Cochlée et voies cochléaires
Ag hbs positif que faire
Ag hbs positif que faire
Line probe assay 26 7-15
Line probe assay 26 7-15
Charlotte pbh du16
Charlotte pbh du16
Bronchite aiguë
Bronchite aiguë
Le système circulatoire ah
Le système circulatoire ah
Cours de sémiologie
Cours de sémiologie
Tuberculose extra-pulmonaire
Tuberculose extra-pulmonaire
Ähnlich wie H pylori poster-web
H. pylori past, present and future
H. pylori past, present and future
Sameh Badr
Ulcer
Ulcer
Shimranz Skillls
Git 4th 5th Gastritis.
Git 4th 5th Gastritis.
Shaikhani.
Usman h.pylori
Usman h.pylori
Muhammad Ameen Rashid Qazi
Peptic ulcer disease
Peptic ulcer disease
Pratik Rahate
annurev-med-042220-020814.pdf
annurev-med-042220-020814.pdf
ArlenElisa1
Helicobacter pylori associated Peptic ulcer disease
Helicobacter pylori associated Peptic ulcer disease
S M Ali Hasan
Diagnosis and Treatment of Helicobacter Pylori Infection
Diagnosis and Treatment of Helicobacter Pylori Infection
DLambertus
H Pylori Management 2023 .pptx
H Pylori Management 2023 .pptx
DrChernHaoChong
Regional Antibiotic Resistance Of Helicobacter Pylori
Regional Antibiotic Resistance Of Helicobacter Pylori
Melissa Dudas
Aetiopathophysiology of peptic ulcer diesese
Aetiopathophysiology of peptic ulcer diesese
Prince Lathiya
H.Pylori
H.Pylori
sunilthomasgeorge217
Proton pump inhibitors present and future a review
Proton pump inhibitors present and future a review
Gulzar Alam
Peptic ulcer
Peptic ulcer
KLE COLLEGE OF PHARMACY
Acid peptic disease nsaids
Acid peptic disease nsaids
raj kumar
Peptic ulcer
Peptic ulcer
Sabbir Hoshen
Presentation on peptic ulcer
Presentation on peptic ulcer
anubhavdubey18
FOCUS ON CURRENT TRENDS IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION
FOCUS ON CURRENT TRENDS IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION
Sarvan Mani
( Peptic ulcer disease ) .pptx
( Peptic ulcer disease ) .pptx
Ahad412190
Infeccion by helicobacter pylori
Infeccion by helicobacter pylori
ravensnake
Ähnlich wie H pylori poster-web
(20)
H. pylori past, present and future
H. pylori past, present and future
Ulcer
Ulcer
Git 4th 5th Gastritis.
Git 4th 5th Gastritis.
Usman h.pylori
Usman h.pylori
Peptic ulcer disease
Peptic ulcer disease
annurev-med-042220-020814.pdf
annurev-med-042220-020814.pdf
Helicobacter pylori associated Peptic ulcer disease
Helicobacter pylori associated Peptic ulcer disease
Diagnosis and Treatment of Helicobacter Pylori Infection
Diagnosis and Treatment of Helicobacter Pylori Infection
H Pylori Management 2023 .pptx
H Pylori Management 2023 .pptx
Regional Antibiotic Resistance Of Helicobacter Pylori
Regional Antibiotic Resistance Of Helicobacter Pylori
Aetiopathophysiology of peptic ulcer diesese
Aetiopathophysiology of peptic ulcer diesese
H.Pylori
H.Pylori
Proton pump inhibitors present and future a review
Proton pump inhibitors present and future a review
Peptic ulcer
Peptic ulcer
Acid peptic disease nsaids
Acid peptic disease nsaids
Peptic ulcer
Peptic ulcer
Presentation on peptic ulcer
Presentation on peptic ulcer
FOCUS ON CURRENT TRENDS IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION
FOCUS ON CURRENT TRENDS IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION
( Peptic ulcer disease ) .pptx
( Peptic ulcer disease ) .pptx
Infeccion by helicobacter pylori
Infeccion by helicobacter pylori
Mehr von Elsa von Licy
Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
Elsa von Licy
Strategie Decisions Incertitude Actes conference fnege xerfi
Strategie Decisions Incertitude Actes conference fnege xerfi
Elsa von Licy
Rainville pierre
Rainville pierre
Elsa von Licy
Neuropsychophysiologie
Neuropsychophysiologie
Elsa von Licy
L agressivite en psychanalyse (21 pages 184 ko)
L agressivite en psychanalyse (21 pages 184 ko)
Elsa von Licy
C1 clef pour_la_neuro
C1 clef pour_la_neuro
Elsa von Licy
Hemostase polycop
Hemostase polycop
Elsa von Licy
Antiphilos
Antiphilos
Elsa von Licy
Vuillez jean philippe_p01
Vuillez jean philippe_p01
Elsa von Licy
Spr ue3.1 poly cours et exercices
Spr ue3.1 poly cours et exercices
Elsa von Licy
Plan de cours all l1 l2l3m1m2 p
Plan de cours all l1 l2l3m1m2 p
Elsa von Licy
M2 bmc2007 cours01
M2 bmc2007 cours01
Elsa von Licy
Feuilletage
Feuilletage
Elsa von Licy
Chapitre 1
Chapitre 1
Elsa von Licy
Biophy
Biophy
Elsa von Licy
Bioph pharm 1an-viscosit-des_liquides_et_des_solutions
Bioph pharm 1an-viscosit-des_liquides_et_des_solutions
Elsa von Licy
Poly histologie-et-embryologie-medicales
Poly histologie-et-embryologie-medicales
Elsa von Licy
Methodes travail etudiants
Methodes travail etudiants
Elsa von Licy
Atelier.etude.efficace
Atelier.etude.efficace
Elsa von Licy
There is no_such_thing_as_a_social_science_intro
There is no_such_thing_as_a_social_science_intro
Elsa von Licy
Mehr von Elsa von Licy
(20)
Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
Strategie Decisions Incertitude Actes conference fnege xerfi
Strategie Decisions Incertitude Actes conference fnege xerfi
Rainville pierre
Rainville pierre
Neuropsychophysiologie
Neuropsychophysiologie
L agressivite en psychanalyse (21 pages 184 ko)
L agressivite en psychanalyse (21 pages 184 ko)
C1 clef pour_la_neuro
C1 clef pour_la_neuro
Hemostase polycop
Hemostase polycop
Antiphilos
Antiphilos
Vuillez jean philippe_p01
Vuillez jean philippe_p01
Spr ue3.1 poly cours et exercices
Spr ue3.1 poly cours et exercices
Plan de cours all l1 l2l3m1m2 p
Plan de cours all l1 l2l3m1m2 p
M2 bmc2007 cours01
M2 bmc2007 cours01
Feuilletage
Feuilletage
Chapitre 1
Chapitre 1
Biophy
Biophy
Bioph pharm 1an-viscosit-des_liquides_et_des_solutions
Bioph pharm 1an-viscosit-des_liquides_et_des_solutions
Poly histologie-et-embryologie-medicales
Poly histologie-et-embryologie-medicales
Methodes travail etudiants
Methodes travail etudiants
Atelier.etude.efficace
Atelier.etude.efficace
There is no_such_thing_as_a_social_science_intro
There is no_such_thing_as_a_social_science_intro
H pylori poster-web
1.
Helicobacter pylori David Y.
Graham and Emad M. El-Omar Supplement to Nature Publishing Group journals Helicobacter pylori is a common and important human pathogen and the primary cause of peptic ulcer disease and gastric cancer. H. pylori is transmitted between humans and is facilitated by poor household hygiene and sanitary conditions. The pathogen causes progressive gastric mucosal inflammation that might eventuate in atrophic gastritis and gastric atrophy. For a population, elimination of H. pylori will Risk factors for gastric cancer Environmental ■ Smoking ■ Diet high in salt ■ Diet low in fresh fruit and vegetables ■ Iron deficiency Bacterial Clinical outcomes of infection Host genetics ■ Genes associated with increased risk of H. pylori infection: TLR1 ■ Genes associated with increased risk of gastric cancer: IL1B, TNF, IL8, PSCA vacA VacA essentially eliminate gastric cancer risk. For the individual, H. pylori eradication will reduce gastric cancer risk depending on the extent of damage (that is, level of risk) when eradication is accomplished. Where gastric cancer is common, H. pylori eradication should be coupled with assessment of cancer risk to identify whether surveillance for gastric cancer is indicated. oipA cagA cag PAI babA and other adhesin genes cag-encoded TFSS Pore formation BabA etc. OipA Infection H. pylori are spiral-shaped Gram-negative bacteria with polar flagella that can survive in the human gastric mucosa. The bacteria have evolved intricate mechanisms to avoid the bactericidal acid in the gastric lumen and to survive near to, to attach to, and to subvert the human gastric epithelium and immune system. Treatment of H. pylori Duodenal ulcer stomach 10–15% of infected people Antral predominant gastritis Acid secretion Asymptomatic stomach Most common phenotype Nonatrophic pangastritis Normal acid secretion Photo ■ H. pylori colonization of the stomach can result in severe gastric pathology ■ H. pylori infection is the strongest known risk factor for gastroduodenal ulcer development; infection is present in 95% of duodenal ulcers and 60–80% of gastric ulcers ■ H. pylori is also causally related to gastric adenocarcinoma ■ The pattern of gastritis predicts the risk of different outcomes, but gastritis tends to progress leading to gastric atrophy ■ The risk of serious clinical outcomes is related to interactions between the host, bacteria and environment Photo Gastric ulcer stomach 1–12% of infected people Progressive atrophy Progressive decrease in acid secretion Gastric cancer stomach 1–12% of infected people Atrophic pangastritis leading to gastric atrophy Acid secretion Normal Atrophy H. pylori infection Treatment requires antibiotics to kill the bacteria and anti-acid medications to ensure they are effective in the stomach. Which therapy? For most other infections, culture is available and specific antibiotics can be chosen. With H. pylori, this approach is generally unavailable and the doctor must use other factors to decide. Considerations Knowledge of antibiotic usage in the population and information about the presence of resistance in the region or other similar regions provides a basis for considering some antibiotics and not others. Discussion with the patient and identifying which antibiotics have been used in the past provides information about possible resistance, as H. pylori often becomes resistant when single antibiotics are used for other infections. Their prior use might exclude them from specific H. pylori therapy. History of antibiotic use? Previously treated for H. pylori? Available Susceptibility testing Tailored Rx Not available Treatment naive: no prior macrolide, fluoroquinolone, metronidazole use Concomitant therapy for 14 days or best locally approved Rx Rx failure At risk for clarithromycinmetronidazole resistance or prior treatment failure Bismuth-PPI-tetracyclinemetronidazole quadruple therapy for 10–14 days or best alternate locally approved Rx All consensus statements agree that whenever H. pylori is diagnosed it should be cured if possible. H. pylori eradication reduces gastric cancer risk. In regions where gastric cancer is common, such as Japan, it is prudent to also assess gastric cancer risk to ascertain whether marked risk remains and, thus, whether surveillance for subsequent gastric cancer might be indicated. Current available drugs Antibiotic regimen* Clarithromycin Amoxicillin Metronidazole PPI Bismuth Levofloxacin – – – – – – – Concomitant (14 days) Tetracycline – – Hybrid (14 days) Risk stratification: is surveillance needed? Diagnosis of H. pylori H. pylori is transmitted between humans and is facilitated by poor household hygiene and sanitary conditions. As such, the bacterium is disappearing in societies with good sanitation, clean water and high standards of living, but remains most common where these conditions are still lacking. Epidemiology The incidence rate of H. pylori infection is far greater in resource-constrained areas, including South America and Africa, than in industrialized countries including North America and the UK. Of note, the prevalence of H. pylori in industrialized countries is often higher among immigrant populations. Incidence of H. pylori (%) 20–30 31–40 41–50 70–80 81–90 Noninvasive (preferred) ■ Serology: IgG against H. pylori ■ Stool antigen test ■ Breath test for diagnosis of H. pylori infection 13 C Urea Urease CO2 in breath 13 CO2 + NH3 Invasive (requires endoscopy) ■ Histology: gastric biopsy samples stained for H. pylori using haematoxylin and eosin, immunohistochemistry, silver staining, Genta stain or alcian yellow–toluidine blue ■ Culture of gastric biopsy samples ■ Rapid urease test Biopsy samples from the stomach antrum Urea and pH indicator (e.g. phenol red) CO2 in blood 13 The patient is given a drink containing urea labelled with nonradioactive carbon-13. If H. pylori is present, their urease enzyme breaks down urea to form carbon dioxide, which is exhaled. After taking the urea-based drink, the patient blows into the sample tube or bag which is then tested for an increase in the proportion of carbon dioxide containing carbon-13. A positive result indicates presence of H. pylori and the appropriate eradication therapy can then be prescribed. Aptalis Pharma Inc. is a privately held, leading specialty pharmaceutical company providing PPI PSCA TFSS TLR1 TNF For more information, visit www.aptalispharma.com. H. pylori positive If H. pylori is present, urea is converted into ammonia and carbon dioxide by their urease enzymes. The breakdown of urea increases the pH level of the solution, triggering a colour change from yellow to pink. Abbreviations innovative, effective therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. Aptalis has manufacturing and commercial operations in the United States, the European Union and Canada. Aptalis also formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary technology platforms including bioavailability enhancement of poorly soluble drugs, custom release profiles, and taste-masking/orally disintegrating tablet (ODT) formulations. H. pylori negative proton pump inhibitor prostate stem cell antigen type IV secretion system Toll-like receptor 1 tumour necrosis factor References 1. Malfertheiner, P. et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Low gastric cancer incidence High gastric cancer incidence Days 1–7 – Days 8–14 Bismuth (10–14 days) Test for H. pylori Pepsinogen testing in serum and eradication treatment Normal levels Low levels Endoscopy for atrophic changes Eradication treatment No atrophy Confirm eradication success – – Clarithromycin‡ (14 days) No follow-up required Moderate–severe atrophy Surveillance ■ Pepsinogens are proteolytic stomach enzymes and are useful noninvasive biomarkers of gastric atrophy ■ Pepsinogen I is present in the gastric corpus; pepsinogen II is present in the gastric corpus and antrum ■ Low serum levels of pepsinogen I or a low pepsinogen I:II ratio is associated with gastric atrophy, which is then confirmed using endoscopy European Helicobacter Study Group. Gut 61, 646–664 (2012). Latest Maastricht Guidelines consensus paper, relevant to diagnosis, treatment and indications for treatment. 2. Cancer Research UK. Stomach cancer incidence [online] http://www.cancerresearchuk.org/cancer-info/cancerstats/world/ stomach-cancer-world/ (2011). 3. The Helicobacter Foundation. Epidemiology [online] http://www.helico.com/?q=Epidemiology (2013). 4. Amieva, M. & El-Omar, E. M. Host–bacterial interactions of Helicobacter pylori infection. Gastroenterology 134, 306–323 (2008). – – – – – – – – – – – – – – Sequential (14 days) § Days 1–7 Test for H. pylori – – Days 8–14 Levofloxacin|| (14 days) – – – *All regimens are useful as tailored therapies when treating based on known antibiotic susceptibility patterns. ‡Limited to low clarithromycin-resistance areas (<5%). §Limited to low metronidazole-resistance areas (<20%). ||Limited to low fluoroquinolone-resistance areas (<5%). In the USA, the prevalence of resistance is ~15% to clarithromycin and 25% to metronidazole, but is much higher in individuals who have taken those antibiotics for other infections. If susceptibility of the pathogen is known, a number of regimens will be effective. If not, the preferred regimens in Western countries are 14-day concomitant therapy and 10–14 day bismuth-quadruple therapy. Choice depends on patient and physician preference and specific allergies or interactions with other drugs the patient is taking. As failure does not stop progression of the disease and treatment failures are common, a noninvasive test for cure is recommended. Indications for eradication ■ Confirmed H. pylori infection ■ Peptic ulcer disease ■ Gastric MALT lymphoma ■ First-degree relative of patient with gastric cancer ■ After curative endoscopic resection of primary gastric cancer ■ Non-ulcer dyspepsia ■ Long-term use of PPI therapy ■ Chronic aspirin or nonsteroidal anti-inflammatory drug therapy 5. Polk, D. B. & Peek, R. M. Jr. Helicobacter pylori: gastric cancer and beyond. Nat. Rev. Cancer 10, 403–414 (2010). 6. Mayerle, J. et al. Identification of genetic loci associated with Helicobacter pylori serologic status. JAMA 309, 1912–1920 (2013). 7. Graham, D. Y., Lee, Y.-C. & Wu, M.-S. Rational Helicobacter pylori therapy: Evidence-based medicine rather than medicine-based evidence. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/ j.cgh.2013.05.028. Future medical therapies The cause of gastric cancer is known —H. pylori infection. The Japanese government approved population-wide H. pylori eradication in 2013 as part of their gastric cancer prevention programme. Hopefully, this action will prompt other governments to ask why H. pylori is not eradicated from their populations. In developing countries, the burden of H. pylori is high and reinfection following curative therapy is common. A vaccine to prevent H. pylori would potentially solve this problem. Despite a number of attempts to develop an H. pylori vaccine for humans, progress has been slow and funding has been scarce. We eagerly await a breakthrough to make this possible. Affiliations and acknowledgements Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard, Houston, TX 77030, USA (D. Y. Graham). Division of Applied Medicine, Institute of Medical Sciences, School of Medicine & Dentistry, Aberdeen University, Foresterhill, Aberdeen AB25 2ZD, UK (E. M. El-Omar). Edited by Katherine Smith. Designed by Laura Marshall. The poster content is peer reviewed, editorially independent and the sole responsibility of Nature Publishing Group. © 2013 Nature Publishing Group. http://www.nature.com/nrgastro/posters/helicobacterpylori
Jetzt herunterladen